Impact of Parkinson’s Medications on Gut Microbiome and Its Implications for Symptom Management and Disease Progression
Faculty Mentor
Xinyi Huang
Major/Area of Research
Pharmacy
Description
INTRODUCTION: Parkinson’s Disease is a chronic neurodegenerative disease and growing public health challenge. Recent advancement in research have explored the relationship between Parkinson’s Disease treatments and gut microbiota.
METHOD: This systematic review aimed to examine the impact of Parkinson’s Disease medications on the gut microbiome. A systematic literature search was performed in the Medline/Pubmed for studies that evaluate gut microbiome metabolizing medications in human. Of the 2074 articles assessed, 8 met the inclusion criteria and investigated the effects of Parkinson’s Disease treatments on the gut microbial composition.
CONCLUSION: Findings from this study highlighted that Parkinson’s Disease medications can significantly alter the gut microbiome, with potential implications for disease progression and treatment efficacy. As a result, further research needs to be implemented into therapeutic strategies targeting the gut microbiome to improve patient outcomes in Parkinson’s Disease management.
Impact of Parkinson’s Medications on Gut Microbiome and Its Implications for Symptom Management and Disease Progression
INTRODUCTION: Parkinson’s Disease is a chronic neurodegenerative disease and growing public health challenge. Recent advancement in research have explored the relationship between Parkinson’s Disease treatments and gut microbiota.
METHOD: This systematic review aimed to examine the impact of Parkinson’s Disease medications on the gut microbiome. A systematic literature search was performed in the Medline/Pubmed for studies that evaluate gut microbiome metabolizing medications in human. Of the 2074 articles assessed, 8 met the inclusion criteria and investigated the effects of Parkinson’s Disease treatments on the gut microbial composition.
CONCLUSION: Findings from this study highlighted that Parkinson’s Disease medications can significantly alter the gut microbiome, with potential implications for disease progression and treatment efficacy. As a result, further research needs to be implemented into therapeutic strategies targeting the gut microbiome to improve patient outcomes in Parkinson’s Disease management.